EICHORCondition: Essential Thrombocythemia · Sponsor: Merck Sharp & Dohme LLC
This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythemia (ET) who have an inadequate response to or are intolerant of hydroxyurea. The primary study hypothesis is that bomedemstat is superior to the best available therapy with respect to durable clinicohematologic response (DCHR).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Palo Verde Hematology/ Oncology Center, Ltd. ( Site 3496) | Glendale, Arizona, United States | — |
| Los Angeles Cancer Network ( Site 3491) | Glendale, California, United States | — |
| Stanford Cancer Institute ( Site 0107) | Stanford, California, United States | — |
| The Lundquist Institute ( Site 3423) | Torrance, California, United States | — |
| University of Colorado Anschutz Medical Campus ( Site 3425) | Aurora, Colorado, United States | — |
| Tufts Medical Center ( Site 3408) | Boston, Massachusetts, United States | — |
| University of Michigan ( Site 0008) | Ann Arbor, Michigan, United States | — |
| Henry Ford Hospital ( Site 3413) | Detroit, Michigan, United States | — |
| Optum Care Cancer Center ( Site 3497) | Las Vegas, Nevada, United States | — |
| Roswell Park Cancer Institute ( Site 3421) | Buffalo, New York, United States | — |
| Duke University Health System (DUHS) ( Site 0016) | Durham, North Carolina, United States | — |
| Wake Forest Baptist Health-Internal Medicine, Section on Hematology & Oncology ( Site 3400) | Winston-Salem, North Carolina, United States | — |
+ 151 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06079879